ANL | Jotup

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Retrieved on:

Friday, March 29, 2024

MSD, Biochemistry, Daiichi Sankyo, Patient, Knowledge, CMC, Cancer, University, Head, Spacecraft, Senior, Research and development, Drug development, Molecular biology, ANL, Pharmaceutical industry

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.

Key Points:

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Dr. Archie Tse as Head of Research & Development, reporting to Mr. Carsten Lu, CEO and Chairman of Adlai Nortye, effective March 29th, 2024.
Prior to joining Adlai Nortye, Dr. Tse served as the Chief Scientific Officer, Senior Vice President, Head of Research and Early Clinical Development, and Head of CMC at CStone Pharmaceuticals, at which he provided strategic leadership and oversight to the research, early clinical development, and CMC aspects of the entire CStone’s pipeline.
“We are very pleased to have Dr. Tse join our senior leadership team,” said Carsten Lu, CEO and Chairman of Adlai Nortye.
“I'm keen to leveraging my experiences with the outstanding team at Adlai Nortye and unlock the full potential of our pipeline.”

Archer Miniaturises Biochip gFET Chip Design

Retrieved on:

Friday, March 15, 2024

Semiconductor, Health, Technology, Other Technology, Other Health, Hardware, Biochip, Electronics, ASX, AXE, ANL

The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology.

Key Points:

The new miniaturised design has been sent to a foundry partner for a whole-wafer fabrication of reduced size gFET chips, which Archer intends to integrate with other parts of the Biochip technology.
The new gFET chip design has been significantly reduced in size over earlier designs of 10mm x 10mm to 1.5mm x 1.5mm.
This includes the creation of a new miniaturised Biochip gFET chip design, sending the design for a whole wafer run in a commercial foundry, and deciding on the chip assembly and semiconductor device electronics packaging and related electrical testing.
Commenting on the miniaturisation of the Biochip gFET chip design, Dr Mohammad Choucair, CEO of Archer, said, “The significant reduction in the size of the Biochip was a great achievement by the Archer team.

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Retrieved on:

Friday, November 17, 2023

Paclitaxel, HNSCC, Treatment, PI3K, Patient, ANL, Trial of the century, Metastasis, Pharmaceutical industry

This clinical study evaluates buparlisib (AN2025), an oral pan-PI3K inhibitor, in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Key Points:

This clinical study evaluates buparlisib (AN2025), an oral pan-PI3K inhibitor, in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
This represents the first global multicenter phase III trial for HNSCC in the class of PI3K inhibitors.
"There is a high unmet medical need for patients with recurrent or metastatic HNSCC after anti-PD-1/anti-PD-L1 therapy.
As the trial is now fully enrolled, we eagerly look forward to the results which may change the paradigm of second-line treatment for HNSCC and provide a new treatment option for patients worldwide," said Lars Birgerson, President and Chief Medical Officer of Adlai Nortye Ltd.

Cerebras Systems Announces 130x Performance Improvement on Key Nuclear Energy Simulation over Nvidia A100 GPUs

Retrieved on:

Monday, November 13, 2023

Cerebras Systems , the pioneer in accelerating generative AI, today announced the achievement of a 130x speedup over Nvidia A100 GPUs on a key nuclear energy HPC simulation kernel, developed by researchers at Argonne National Laboratory.

Key Points:

Cerebras Systems , the pioneer in accelerating generative AI, today announced the achievement of a 130x speedup over Nvidia A100 GPUs on a key nuclear energy HPC simulation kernel, developed by researchers at Argonne National Laboratory.
This result demonstrates the performance and versatility of the Cerebras Wafer-Scale Engine (WSE-2) and ensures that the U.S. continues to be the global leader in supercomputing for energy and defense applications.
This kernel represents the most computationally intensive portion of the full simulation, accounting for up to 85% of the total runtime for many nuclear energy applications.
“These published results highlight not only the incredible performance of the CS-2, but also its architectural efficiency,” said Andrew Feldman, CEO and co-founder of Cerebras Systems.

DAOS Foundation Launches to Broaden Governance and Development of the Distributed Asynchronous Object Storage Project

Retrieved on:

Thursday, November 9, 2023

SAN FRANCISCO, Nov. 9, 2023 /PRNewswire/ -- The Linux Foundation is excited to announce the launch of the DAOS Foundation, an initiative aimed at advancing the governance and development of the Distributed Asynchronous Object Storage (DAOS) project. Featuring broad support from founding members Argonne National Laboratory (ANL), Enakta Labs, Google Cloud, Hewlett Packard Enterprise (HPE), and Intel, this significant milestone represents a major step toward accelerating next-generation High Performance Computing (HPC), and Artificial Intelligence and Machine Learning (AI/ML), with unprecedented performance.

Key Points:

SAN FRANCISCO, Nov. 9, 2023 /PRNewswire/ -- The Linux Foundation is excited to announce the launch of the DAOS Foundation , an initiative aimed at advancing the governance and development of the Distributed Asynchronous Object Storage (DAOS) project.
The Distributed Asynchronous Object Storage (DAOS) is a high performance open source storage system that has redefined performance for a wide spectrum of HPC and AI workloads.
To provide a broader governance to the project and to foster future development and growth, the DAOS Foundation has launched as a project under the umbrella of the Linux Foundation.
To learn more about the DAOS Foundation, including how to become a member and join their community, please visit the DAOS Foundation website at https://foundation.daos.io/ .

Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award

Retrieved on:

Monday, October 23, 2023

ESMO, Health, SCCHN, Head, Poster, Paclitaxel, Partnership, H&E, Digital pathology, ANL, CMO, NORTH, Patient, Medical imaging, Buparlisib

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.

Key Points:

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a global clinical-stage biotechnology company focused on innovative oncology drugs, and Nucleai, a pathology-based AI-powered biomarker discovery and diagnostics company, is pleased to announce today the receipt of the ESMO 2023 Best Poster Award for the Sunday, October 22, 2023 poster session with the presentation of the study “Utilizing H&E Images and Digital Pathology to Predict Response to Buparlisib in SCCHN”.
We are extremely pleased the study was recognized for its quality and success,” said Dr. Lars Birgerson, President & CMO of Adlai Nortye.
The poster, #869P, was presented at the Head and Neck Cancers poster session on Sunday, October 22, 2023.
The Best Poster Award was given at the conclusion of the Sunday Poster Session.

Adlai Nortye Ltd. Announces Closing of Initial Public Offering

Retrieved on:

Tuesday, October 3, 2023

Attention, NORTH, The Women on the 6th Floor, Capital market, ADS, ANL, Sale, Prospectus, Security (finance)

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares (“ADSs”), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS.

Key Points:

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the closing of its previously announced initial public offering of 2,500,000 American depositary shares (“ADSs”), each representing three Class A ordinary shares at a public offering price of US$23.00 per ADS.
All of the ADSs were offered by Adlai Nortye.
In addition, Nippon Kayaku Co., Ltd., a chemical company headquartered in Japan, acquired a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price.
Adlai Nortye received aggregate gross proceeds of US$57.5 million from the public offering (before deducting underwriting discounts and commissions and offering expenses) and US$40.0 million from the concurrent private placement.

Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

Retrieved on:

Friday, September 29, 2023

Exercise, Attention, NORTH, The Women on the 6th Floor, Capital market, ADS, ANL, Sale, Prospectus, Security (finance)

All of the ADSs were offered by Adlai Nortye.

Key Points:

All of the ADSs were offered by Adlai Nortye.
In addition, an investor will acquire a total of 5,217,391 Class A ordinary shares from Adlai Nortye in a private placement concurrent with the closing of the public offering at the same per share purchase price.
Adlai Nortye expects to receive aggregate gross proceeds of US$97.5 million, including US$57.5 million from the public offering (before deducting underwriting discounts and commissions and offering expenses, and not taking into account potential exercise of the underwriters’ over-allotment option) and US$40.0 million from the concurrent private placement.
Assuming the over-allotment option is exercised in full, the aggregate gross proceeds to be received by Adlai Nortye may reach up to approximately US$106.1 million.

MLCommons Releases New MLPerf Results that Highlight Growing Importance of Generative AI and Storage

Retrieved on:

Monday, September 11, 2023

This publication marks the first ever release of results from the MLPerf Storage benchmark, which measures the performance of storage systems in the context of ML training workloads.

Key Points:

This publication marks the first ever release of results from the MLPerf Storage benchmark, which measures the performance of storage systems in the context of ML training workloads.
In particular, MLCommons® would like to congratulate first time MLPerf Inference submitters Connect Tech, Nutanix, Oracle, and TTA.
The MLPerf Storage Benchmark Suite is the first open-source AI/ML benchmark suite that measures the performance of storage for ML training workloads.
To view the results for MLPerf Inference v3.1 and MLPerf Storage v0.5, and to find additional information about the benchmarks please visit:

ANSI Publishes Roadmap of Standards and Codes for Electric Vehicles at Scale

Retrieved on:

Thursday, June 15, 2023

NEW YORK, June 15, 2023 /PRNewswire/ -- The American National Standards Institute (ANSI) announced today the publication of the Roadmap of Standards and Codes for Electric Vehicles at Scale developed by the Institute's Electric Vehicles Standards Panel ( EVSP ).

Key Points:

NEW YORK, June 15, 2023 /PRNewswire/ -- The American National Standards Institute (ANSI) announced today the publication of the Roadmap of Standards and Codes for Electric Vehicles at Scale developed by the Institute's Electric Vehicles Standards Panel ( EVSP ).
It is hoped that the roadmap will see broad adoption by the user community and will facilitate a more coherent and coordinated approach to the future development of standards for EVs.
The ANSI EVSP does not develop standards but serves solely as a forum for facilitating coordination among SDOs and others.
ANSI's facilitation of the EVSP's roadmap initiative was supported in part by VTO/ANL and UL Standards & Engagement, among others.